| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db628fbc812ea146bb6eb24a8c0ab43a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2014-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7163a1b8af7fbb4377c0cb2f583dd11e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77859c0ff91831656d10945c53e9bb2a |
| publicationDate |
2016-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3047034-A1 |
| titleOfInvention |
Biomarkers correlated to parp inhibitor treatment success in aml patients |
| abstract |
In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML. |
| priorityDate |
2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |